Key insights
- Johnson & Johnson is presenting data on its neuropsychiatry portfolio, including CAPLYTA, seltorexant, and SPRAVATO, at upcoming medical conferences. The presentations cover major depressive disorder, treatment-resistant depression, and schizophrenia. The news highlights J&J's commitment to this therapeutic area and the potential for growth in its pharmaceutical division. The impact on US equities is slightly positive, reflecting potential revenue growth.
TITUSVILLE, N.J. - Johnson & Johnson (NYSE:JNJ) announced Monday that 18 abstracts from its neuropsychiatry portfolio will be presented at the American Psychiatric Association Annual Meeting from May 16-20 in San Francisco and the American Society of Clinical Psychopharmacology Annual Meeting from May 26-29 in Miami, according to a press release statement.
The presentations will feature data on CAPLYTA (lumateperone), seltorexant, and SPRAVATO (esketamine) nasal spray across major depressive disorder, treatment-resistant depression, and schizophrenia.
At the APA meeting, an oral presentation will discuss long-term data from a CAPLYTA Phase 3 study evaluating safety and efficacy for relapse prevention in schizophrenia. At the ASCP meeting, an oral presentation will present Phase 3 data on seltorexant as adjunctive therapy in adults with major depressive disorder and insomnia symptoms.
Additional ASCP presentations include poster sessions on CAPLYTA analyzing remission outcomes and efficacy in major depressive disorder patient subgroups, SPRAVATO post-hoc analyses examining relapse predictors in treatment-resistant depression patients, and recommendations for presenting long-acting injectables to schizophrenia patients.
CAPLYTA 42 mg is approved as adjunctive therapy with antidepressants for major depressive disorder, for schizophrenia, and for bipolar depression. Seltorexant is an investigational selective orexin-2 receptor antagonist being developed as adjunctive treatment for major depressive disorder with insomnia symptoms. SPRAVATO is approved for treatment-resistant depression and depressive symptoms in major depressive disorder with acute suicidal ideation or behavior.
The company stated the presentations underscore its commitment to advancing treatment options for neuropsychiatric conditions.
In other recent news, Johnson & Johnson announced that the U.S. Food and Drug Administration has approved an expanded label for Caplyta, a drug used in the prevention of relapse in schizophrenia. This approval is based on long-term data evaluating the drug’s safety and efficacy. In a separate development, Johnson & Johnson reported promising results from Phase 2b studies of its investigational therapy, JNJ-4804, for ulcerative colitis and Crohn’s disease, showing improved clinical remission and endoscopic response rates compared to other treatments. Additionally, the company revealed that its drug Tremfya met the primary endpoint in a Phase 3 study for fistulizing Crohn’s disease, demonstrating statistically significant treatment differences compared to a placebo.
Furthermore, Johnson & Johnson appointed Ryan Koors as Vice President of Investor Relations, effective May 7, 2026. Koors will be reporting to Joseph J. Wolk, the company’s Executive Vice President and Chief Financial Officer. Meanwhile, CVS Health announced it will prioritize lower-cost biosimilars over Johnson & Johnson’s psoriasis drug Stelara in its drug lists starting July 1. These developments reflect ongoing strategic and clinical advancements within Johnson & Johnson.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.